RT Journal Article
SR Electronic
T1 Metabolomic Imaging for Human Prostate Cancer Detection
JF Science Translational Medicine
FD American Association for the Advancement of Science
SP 16ra8
OP 16ra8
DO 10.1126/scitranslmed.3000513
VO 2
IS 16
A1 Wu, Chin-Lee
A1 Jordan, Kate W.
A1 Ratai, Eva M.
A1 Sheng, Jinhua
A1 Adkins, Christen B.
A1 DeFeo, Elita M.
A1 Jenkins, Bruce G.
A1 Ying, Leslie
A1 McDougal, W. Scott
A1 Cheng, Leo L.
YR 2010
UL http://stm.sciencemag.org/content/2/16/16ra8.abstract
AB As current radiological approaches cannot accurately localize prostate cancer in vivo, biopsies are conducted at random within prostates for patients at risk for prostate cancer, leading to high false-negative rates. Metabolomic imaging can map cancer-specific biomolecular profile values onto anatomical structures to direct biopsy. In this preliminary study, we evaluated five whole prostates removed during prostatectomy from biopsy-proven cancer patients on a 7-tesla human whole-body magnetic resonance scanner. Localized, multi–cross-sectional, multivoxel magnetic resonance spectra were used to construct a malignancy index based on prostate cancer metabolomic profiles obtained from previous intact tissue analyses with a 14-tesla spectrometer. This calculated malignancy index is linearly correlated with lesion size and demonstrates a 93 to 97% overall accuracy for detecting the presence of prostate cancer lesions, suggesting the potential clinical utility of this approach. Copyright © 2010, American Association for the Advancement of Science